Current Advances in Retroviral Gene Therapy

  • Yi Y
  • Jong Noh M
  • Hee Lee K
92Citations
Citations of this article
238Readers
Mendeley users who have this article in their library.

Abstract

There have been major changes since the incidents of leukemia development in X-SCID patients after the treatments using retroviral gene therapy. Due to the risk of oncogenesis caused by retroviral insertional activation of host genes, most of the efforts focused on the lentiviral therapies. However, a relative clonal dominance was detected in a patient with β-thalassemia Major, two years after the subject received genetically modified hematopoietic stem cells using lentiviral vectors. This disappointing result of the recent clinical trial using lentiviral vector tells us that the current and most advanced vector systems does not have enough safety. In this review, various safety features that have been tried for the retroviral gene therapy are introduced and the possible new ways of improvements are discussed. Additional feature of chromatin insulators, co-transduction of a suicidal gene under the control of an inducible promoter, conditional expression of the transgene only in appropriate target cells, targeted transduction, cell type-specific expression, targeted local administration, splitting of the viral genome, and site specific insertion of retroviral vector are discussed here.

Cite

CITATION STYLE

APA

Yi, Y., Jong Noh, M., & Hee Lee, K. (2011). Current Advances in Retroviral Gene Therapy. Current Gene Therapy, 11(3), 218–228. https://doi.org/10.2174/156652311795684740

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free